Neuroleptic malignant syndrome
| Autor: | Artur Furlaneto Fernandes, Hélio A.G. Teive, Tabita Tomelin, Felipe T. M. Novak, Renato P. Munhoz, Edison Matos Nóvak, Mariana Moscovich, Tatiana P. Bruch |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Pediatrics neuroleptic malignant syndrome Adolescent Cross-sectional study Signs and symptoms lcsh:RC321-571 Young Adult High doses Humans Neuroleptic Malignant Syndrome Medicine typical antipsychotics neurolépticos típicos síndrome neuroléptica maligna neurolépticos atípicos Established diagnosis Young adult Adverse effect lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Aged Aged 80 and over Past medical history business.industry atypical antipsychotics Middle Aged medicine.disease Surgery Neuroleptic malignant syndrome Cross-Sectional Studies Neurology Female Neurology (clinical) business Antipsychotic Agents |
| Zdroj: | Arquivos de Neuro-Psiquiatria, Volume: 69, Issue: 5, Pages: 751-755, Published: OCT 2011 Arquivos de Neuro-Psiquiatria v.69 n.5 2011 Arquivos de neuro-psiquiatria Academia Brasileira de Neurologia instacron:ABNEURO Arquivos de Neuro-Psiquiatria, Vol 69, Iss 5, Pp 751-755 (2011) |
| Popis: | Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS. A síndrome neuroléptica maligna (SNM) é um evento adverso potencialmente fatal associado ao uso de antipsicóticos (AP). O objetivo deste estudo foi investigar as características clínicas de cases da SNM e comparar nossos resultados com os publicados na literatura. Uma série de 18 pacientes com diagnóstico confirmado de SNM foram analisados, associando dados demográficos, apresentação clínica, diagnóstico e tratamento. Dois terços dos casos envolveram mulheres com antecedentes psiquiátricos que recebeceram doses relativamente altas de AP. Os sinais e sintomas foram semelhantes àqueles já relatados na literatura e a maioria dos pacientes teve uma recuperação completa, exceto por um caso com desfecho fatal. Houve predomínio de pacientes que usam medicamentos neurolépticos clássicos (68%), porém não houve diferença nas manifestações destes casos em relação àqueles que usavam AP novos. AP mais novos também têm o potencial de causar SNM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|